• Jiamin Liu, Fengxian Zheng, Meng Yang, Xiaoyong Wu, and Aimin Liu.
• College of Medicine, Guangxi University of Traditional Chinese Medicine, Nanning, China.
• Medicine (Baltimore). 2021 Aug 20; 100 (33): e26870e26870.

ObjectiveThe purpose of this study is to investigate whether aspirin improves the prognosis of breast cancer patients by meta analysis.MethodsSearched PubMed, EMBASE, and other databases for literature on the relationship between aspirin use and breast cancer prognosis, with the deadline of October 2019. The related results of all-cause death, breast cancer-specific death, and breast cancer recurrence/metastasis were extracted to combine the effect amount. The sensitivity analysis and published bias analysis were carried out for the included data. Stata12.0 software was used to complete all statistical analysis.ResultsA total of 13 papers were included in the study, including 142,644 breast cancer patients. The results of meta-analysis showed that patients who took aspirin were associated with lower breast cancer-specific death (HR = 0.69, 95% CI = 0.61-0.76), all-cause death (HR = 0.78, 95% CI = 0.71-0.84), and risk of recurrence/metastasis (HR = 0.91, 95% CI: 0.82-1.00).ConclusionsAspirin use may improve all-cause mortality, specific mortality, and risk of recurrence/metastasis in patients with breast cancer.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

23 keywords...

hide…